02:17 PM EDT, 07/09/2025 (MT Newswires) -- Hemostemix ( HMTXF ) on Wednesday said its non brokered private placement of $2.5 million announced on June 26 is oversubscribed.

The company said it will close the first tranche of $2.7 million on July 10.

Hemostemix ( HMTXF ) said the purchasers subscribed for units at $0.10. Each unit is made up of a share and one two-year warrant to buy a share for $0.15.

Proceeds will be used for "a repayment of CD#1 in full," and general working capital in support of the company's continuing operational expenses, including marketing and sales of the VesCell.

Additionally, the company said it negotiated the settlement of $400,000 of debt with its certain creditors at $0.20 per share and that it is completing related filings with the TSXV Exchange.

The company's shares were last seen up $0.005 to $0.14 on the TSX Venture Exchange.

Price: 0.14, Change: +0.01, Percent Change: +3.70